ArticleEndocrine connections2026
Thyroid carcinoma follow-up: tertiary to primary care transition in Portugal.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The transition of differentiated thyroid carcinoma (DTC) care from hospital to primary care remains controversial. Current studies suggest that low-risk patients with an excellent response to therapy are safely followed up by primary care professionals. Despite this, discharge practices among Portuguese thyroidologists remain heterogeneous and the success of this clinical transition is yet unknown. This study aims to evaluate primary care compliance to follow-up recommendations for DTC patients after tertiary care discharge. Methods: A retrospective observational study was conducted including individuals with a history of DTC who were treated in a Portuguese tertiary care hospital and discharged to follow-up at primary care setting, during 2022. Data were collected from electronic records, including thyroglobulin and antithyroglobulin antibody levels. Results: A total of 134 individuals were discharged. The majority (n = 105; 78.4%) were female, with a mean age at discharge of 64 ± 12 years. The most frequent diagnosis was papillary thyroid carcinoma (95.5%, n = 128). Regarding treatment, 52.2% (n = 70) only underwent thyroidectomy, 44.8% (n = 60) underwent thyroidectomy followed by iodine-131 ablation, and 3.0% (n = 4) underwent subtotal thyroidectomy. Most DTC cases (86.6%, n = 116) were classified as low risk and showed an excellent response to treatment (82.1%, n = 110) according to the ATA 2015 Guidelines. One year after discharge, biochemical response evaluated by thyroglobulin and antithyroglobulin levels were registered in 29.1% (n = 39) of individuals. Thirteen patients (9.7%) had records of either antithyroglobulin antibodies or thyroglobulin alone. Conclusion: Patients with low-risk DTC receive suboptimal monitoring after transition to primary care, emphasizing the need to enhance follow-up practices to ensure adequate long-term surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.